Overview

Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy

Status:
Completed
Trial end date:
2018-04-25
Target enrollment:
Participant gender:
Summary
Sixteen week open label study of apremilast in combination with topical steroids with a four week safety follow up visit.
Phase:
Phase 4
Details
Lead Sponsor:
Derm Research, PLLC
Collaborator:
Celgene
Treatments:
Apremilast
Thalidomide